These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 12950416)

  • 1. Review article: the data supporting a role for aminosalicylates in the chemoprevention of colorectal cancer in patients with inflammatory bowel disease.
    Eaden J
    Aliment Pharmacol Ther; 2003 Sep; 18 Suppl 2():15-21. PubMed ID: 12950416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug insight: aminosalicylates for the treatment of IBD.
    Nielsen OH; Munck LK
    Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis.
    Qiu X; Ma J; Wang K; Zhang H
    Oncotarget; 2017 Jan; 8(1):1031-1045. PubMed ID: 27906680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study.
    van Staa TP; Card T; Logan RF; Leufkens HG
    Gut; 2005 Nov; 54(11):1573-8. PubMed ID: 15994215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoprevention: risk reduction with medical therapy of inflammatory bowel disease.
    Chan EP; Lichtenstein GR
    Gastroenterol Clin North Am; 2006 Sep; 35(3):675-712. PubMed ID: 16952746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease.
    Terdiman JP; Steinbuch M; Blumentals WA; Ullman TA; Rubin DT
    Inflamm Bowel Dis; 2007 Apr; 13(4):367-71. PubMed ID: 17206695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesalamine protects against colorectal cancer in inflammatory bowel disease.
    Tang J; Sharif O; Pai C; Silverman AL
    Dig Dis Sci; 2010 Jun; 55(6):1696-703. PubMed ID: 19705280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controversies with aminosalicylates in inflammatory bowel disease.
    Lim WC; Hanauer SB
    Rev Gastroenterol Disord; 2004; 4(3):104-17. PubMed ID: 15359211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease.
    Carrat F; Seksik P; Colombel JF; Peyrin-Biroulet L; Beaugerie L;
    Aliment Pharmacol Ther; 2017 Feb; 45(4):533-541. PubMed ID: 27995656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aminosalicylates.
    Campregher C; Gasche C
    Best Pract Res Clin Gastroenterol; 2011 Aug; 25(4-5):535-46. PubMed ID: 22122769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aminosalicylates and colorectal cancer in IBD: a not-so bitter pill to swallow.
    Ryan BM; Russel MG; Langholz E; Stockbrugger RW
    Am J Gastroenterol; 2003 Aug; 98(8):1682-7. PubMed ID: 12907319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis.
    Rubin DT; LoSavio A; Yadron N; Huo D; Hanauer SB
    Clin Gastroenterol Hepatol; 2006 Nov; 4(11):1346-50. PubMed ID: 17059900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer?
    Bernstein CN; Blanchard JF; Metge C; Yogendran M
    Am J Gastroenterol; 2003 Dec; 98(12):2784-8. PubMed ID: 14687833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study.
    Bernstein CN; Nugent Z; Blanchard JF
    Am J Gastroenterol; 2011 Apr; 106(4):731-6. PubMed ID: 21407180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemoprevention for colon cancer: new opportunities, fact or fiction?
    Terhaar Sive Droste JS; Tuynman JB; Van Dullemen HM; Mulder CJ
    Scand J Gastroenterol Suppl; 2006; (243):158-64. PubMed ID: 16782636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoprevention of colorectal cancer in inflammatory bowel disease.
    Subramanian V; Logan RF
    Best Pract Res Clin Gastroenterol; 2011 Aug; 25(4-5):593-606. PubMed ID: 22122774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease.
    Hanauer SB; Stathopoulos G
    Drug Saf; 1991; 6(3):192-219. PubMed ID: 1676590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of chemoprevention of colorectal cancer with 5-aminosalicylates in ulcerative colitis.
    Herfarth H
    Dig Dis; 2012; 30 Suppl 2():55-9. PubMed ID: 23207933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review article: the effect of aminosalicylates and immunomodulation on cancer risk in inflammatory bowel disease.
    Stange EF
    Aliment Pharmacol Ther; 2006 Oct; 24 Suppl 3():64-7. PubMed ID: 16961748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Primary chemoprevention of colorectal cancer in patients with inflammatory bowel diseases].
    Ioffe AIu
    Lik Sprava; 2005 Jun; (4):45-8. PubMed ID: 16158715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.